Business Wire

Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Share

Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced the full results from the pivotal Phase 2 AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with refractory chronic graft-versus-host disease (GVHD) who had received at least two prior lines of systemic therapy. These data are featured today in the Plenary Scientific Session (Abstract #1) at the 65th American Society of Hematology Annual Meeting 2023 (ASH 2023), held December 9-12, 2023, in San Diego and virtually.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231210634247/en/

The results, which build on previously announced topline data, show that the trial met the primary endpoint across all cohorts receiving axatilimab, at doses of 0.3 mg/kg every two weeks, 1.0 mg/kg every two weeks and 3.0 mg/kg every four weeks. Patients who received axatilimab at 0.3 mg/kg every two weeks achieved the highest overall response rate (ORR) of 74% within the first six months of treatment (95% CI; 63-83). Patients in this cohort experienced a median time to response to axatilimab of 1.7 months (0.9-8.1), and 60% of patients maintained a response at 12 months (measured from first response to new systemic therapy or death, based on the Kaplan Meier estimate). The recommended dose of axatilimab for future trials in chronic GVHD is 0.3 mg/kg every two weeks.

“The data presented today at ASH represent a significant step forward in expanding the treatment options for patients with refractory chronic GVHD,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. "An unmet need remains for treatments that are well tolerated and efficacious for patients with refractory chronic GVHD, and the data presented today show that axatilimab could provide a valuable option. We look forward to working with our partners at Syndax as we move axatilimab towards regulatory filing.”

The AGAVE-201 trial also met key secondary endpoints in the 0.3 mg/kg dose, with 55% of patients achieving a ≥7-point improvement in the modified Lee Symptom Scale (mLSS) score. Organ-specific responses, including complete responses (CRs), were seen across all organs involved at baseline, including lower gastrointestinal (GI), upper GI, esophagus, joints/fascia, mouth, lungs, liver, eyes and skin. Additionally, responses were notable in fibrosis-dominated organs, including the esophagus (78%), joints and fascia (76%), lungs (47%) and skin (27%).

“The additional positive data from AGAVE-201 further strengthen axatilimab’s strong safety and efficacy profile as a well-differentiated treatment option for patients with refractory chronic GVHD,” said Michael A. Metzger, Chief Executive Officer of Syndax. "As a potentially first-in-class anti-CSF-1R antibody targeting inflammation and fibrosis through the inhibition of disease associated macrophages, we have more conviction than ever that axatilimab is poised to transform the treatment paradigm for chronic GVHD. Axatilimab has the potential to positively impact patients with this devastating disease and we are working diligently with Incyte to bring this agent to market.”

The AGAVE-201 pivotal trial enrolled 241 patients with relapsed and refractory cGVHD who had received two or more prior systemic therapies, with 74% having previously received ruxolitinib, 31% having previously received ibrutinib and 23% having previously received belumosudil. Patients were enrolled across 121 sites in 16 countries.

The most common treatment-emergent adverse events (TEAEs) were consistent with the on-target effects of CSF-1R inhibition and with what was previously observed with axatilimab treatment. TEAEs in greater than 20% of patients in the overall population (n=239) include increases in aspartate aminotransferase, blood creatine phosphokinase, lipase, lactate dehydrogenase, and alanine aminotransferase.

In the overall trial population, 33% of patients experienced at least one grade ≥3 TEAE, with 15.5% experiencing adverse events leading to discontinuation of treatment. For patients who received axatilimab at 0.3 mg/kg (n=79), grade ≥3 TEAEs occurred in 17.7% of patients, with 6.3% experiencing TEAEs leading to discontinuation of treatment.

“Approximately 50% of chronic GVHD patients are refractory to first-line treatment and 25% of patients require at least four lines of treatment, representing a great need for additional effective treatment options,” said Daniel Wolff, M.D., Ph.D., Head, Senior Physician, and Professor at University Hospital Regensburg. "Full results from the AGAVE-201 trial show rapid durable responses documented in all organs and patient subgroups, with significant symptom burden reduction reported by most of these heavily-pretreated patients. I am pleased that the results of the AGAVE-201 trial showed potential advances for patients who had not responded to previous lines of treatments and look forward to further research to underscore the efficacy of axatilimab patients with chronic GVHD.”

Based on these results and pending agreement from the U.S. Food and Drug Administration (FDA), Syndax and Incyte expect to submit a Biologics License Application (BLA) to the FDA by year-end 2023.

About Chronic Graft-Versus Host Disease

Chronic graft-versus-host disease (GVHD), an immune response of the donor-derived hematopoietic cells against recipient tissues, is a serious, potentially life-threatening complication of allogeneic hematopoietic stem cell transplantation which can last for years. Chronic GVHD is estimated to develop in approximately 40% of transplant recipients, and affects approximately 14,000 patients in the U.S.1,2. Chronic GVHD typically manifests across multiple organ systems, with skin and mucosa being commonly involved, and is characterized by the development of fibrotic tissue3.

About Axatilimab

Axatilimab is an investigational monoclonal antibody that targets colony stimulating factor-1 receptor, or CSF-1R, a cell surface protein thought to control the survival and function of monocytes and macrophages. In pre-clinical models, inhibition of signaling through the CSF-1 receptor has been shown to reduce the number of disease-mediating macrophages along with their monocyte precursors, which has been shown to play a key role in the fibrotic disease process underlying diseases such as chronic graft-versus-host disease (GVHD) and idiopathic pulmonary fibrosis (IPF). Phase 1/2 data of axatilimab in chronic GVHD demonstrating its broad activity and tolerability were last presented at the 63rd American Society of Hematology Annual Meeting and data were published in the Journal of Clinical Oncology. Additionally, positive topline results from the Phase 2 AGAVE-201 trial showing the trial met its primary endpoint were recently announced. Axatilimab was granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of patients with chronic GVHD and IPF. In September 2021, Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement for axatilimab. Axatilimab is being developed under an exclusive worldwide license from UCB entered into between Syndax and UCB in 2016.

About AGAVE-201

The global Phase 2 AGAVE-201 dose-ranging trial evaluated the efficacy, safety, and tolerability of axatilimab in 241 adult and pediatric patients with recurrent or refractory active chronic GVHD whose disease had progressed after two prior therapies. Patients were randomized to one of three treatment groups that investigated a distinct dose of axatilimab administered at 0.3 mg/kg every two weeks, 1.0 mg/kg every two weeks or 3.0 mg/kg every four weeks. The trial's primary endpoint is the proportion of patients in each dose group who achieved an objective response as defined by 2014 NIH Consensus Criteria for chronic GVHD by cycle 7 day 1. Secondary endpoints include duration of response, percent reduction in daily steroids dose, organ specific response rates and validated quality-of-life assessments using the Modified Lee Symptom Scale.

For more information about AGAVE-201, visit https://www.clinicaltrials.gov/study/NCT04710576.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

About Syndax

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the Menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.

Incyte Forward-looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the AGAVE-201 trial, expectations regarding the submission of a BLA for axatilimab by year-end 2023, and the potential for axatilimab to become a treatment option for chronic graft-versus-host disease, contain predictions, estimates and other forward-looking statements.

These forward-looking statements are based on Incyte's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the U.S. FDA and other regulatory authorities outside of the United States; the efficacy or safety of Incyte and its partners' products; the acceptance of Incyte and its partners' products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in Incyte's reports filed with the Securities and Exchange Commission, including its annual report and its quarterly report on Form 10-Q for the quarter ended September 30, 2023.

Syndax Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend," "believe" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials, the reporting of clinical data for Syndax's product candidates, the potential filing of a BLA by year-end 2023, and the potential use of our product candidates to treat various cancer indications and fibrotic diseases. Many factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; failure of Syndax's collaborators to support or advance collaborations or product candidates; and unexpected litigation or other disputes. Other factors that may cause Syndax's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

1 SmartAnalyst 2020 SmartImmunology Insights chronic GVHD report.

2 Bachier, CR. et al. ASH annual meeting 2019; abstract #2109 Epidemiology and Real-World Treatment of Chronic Graft-Versus-Host Disease Post Allogeneic Hematopoietic Cell Transplantation: A U.S. Claims Analysis.

3 Kantar 2020 GVHD Expert Interviews N=32 interviews.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Incyte Contacts:
Media
media@incyte.com
Investors
ir@incyte.com

Syndax Contact:
Sharon Klahre
sklahre@syndax.com
Tel 781.684.9827

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Interactive Brokers Unveils Next-Generation Trading Platform: IBKR Desktop28.2.2024 16:00:00 CET | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, is excited to introduce IBKR Desktop, the next-generation desktop trading application for Windows and Mac, engineered for today’s traders who demand simplicity but value Interactive Brokers’ powerful trading tools. IBKR Desktop marks a new chapter for innovation and focus on the intuitive user experience at Interactive Brokers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240227650768/en/ Screenshots of IBKR Desktop, left-MultiSort, center-Option Analysis, right-Option Lattice. (Photo: Business Wire) “Interactive Brokers has a rich lineage of delivering market-leading technology. Responding to our clients’ requests for powerful trading tools in a user-friendly interface, we’ve leveraged our experience building cutting-edge trading solutions to create our latest-generation platform. With IBKR Desktop, traders of all levels can enjoy the advanced trad

LTIMindtree Joins Forces with IBM to Advance the Quantum Innovation Ecosystem28.2.2024 15:00:00 CET | Press release

LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, announced that it has joined the IBM Quantum Network to explore quantum computing innovation for the benefit of its global clientele across multiple industries. LTIMindtree is the first Indian Global System Integrator (GSI) to join the IBM Quantum Network. LTIMindtree will also collaborate with the Indian Institute of Technology (IIT) Madras, which is also an IBM Quantum Innovation Center, on joint quantum research and workforce development. Scott Crowder, Vice President of IBM Quantum Adoption and Business Development, said, “We are excited to welcome LTIMindtree into the IBM Quantum Network and to help them explore the benefits of quantum computing, both for their internal teams and in solutions for their clients. We are also looking forward to providing technology support for LTIMindtree’s joint research and educational engagements with IIT-Madras, our first IBM Quantum Innovation Cen

Customers Empowered to Participate in the Circular Economy through New Lenovo Offering28.2.2024 15:00:00 CET | Press release

Lenovo (HKSE: 992) (ADR: LNVGY) is rolling out a new solution to help customers extend the lifecycle of their devices with cost-efficient IT choices for a more sustainable future. Through Lenovo Certified Refurbished, organizations can deploy refurbished PCs that cater to their different computing needs and help manage their IT carbon footprint. Lenovo TruScale Device as a Service (DaaS) customers will also have more options to optimize their IT mix according to their unique economic and business needs, and with circularity in mind. Only Lenovo and accredited partners will offer the Lenovo certification, guaranteeing industry-leading quality devices that businesses can depend on. “Environmental sustainability is a leading concern for businesses of every size, in every sector,” said Claudia Contreras, Executive Director of Global Sustainability Services for Lenovo. “Lenovo Certified Refurbished extends the lifecycle of our technology to improve ROI and help reduce waste, offering a solu

Etam Group Relies on Precisely Automate to Drive Business Agility and Innovation28.2.2024 15:00:00 CET | Press release

Precisely, the global leader in data integrity, today announced that Etam Group, a major international retailer and leading lingerie brand in France, has implemented its Automate Studio solution across all subsidiaries to support company-wide accounts payable processes. By providing seamless SAP data access to decision-makers in real-time, Automate Studio (formerly Winshuttle Studio) enables Etam’s accounting teams to work autonomously without support from IT personnel, reduce operational costs, and drive greater innovation across the organization. Business agility is critical in the retail industry, with companies seeking to balance tight margins with the need to innovate and stay competitive. With more pressure than ever to optimize margins through existing operating structures and processes, it comes as no surprise that automation has emerged as a top consideration for retailers in 2024. Retail companies are increasingly seeing the need to simplify and accelerate processes across th

MATI and Mescalero Apache Tribe drive ultra-fast connectivity to remote tribal communities with Adtran Mosaic One28.2.2024 14:00:00 CET | Press release

Adtrantoday announced that Mescalero Apache Telecom, Inc. (MATI) is harnessing its fiber access solution to bring high-speed connectivity to rural tribal communities in New Mexico. Supported by a mix of loans and grant funds, MATI’s new infrastructure is the first full FTTH XGS-PON network to be built among any tribal nation. Part of the Broadband Infrastructure Deployment initiative, the solution will deliver symmetrical Gigabit services to the Mescalero Apache reservation. The deployment is set to have a significant impact on the community, empowering residents with access to critical online resources such as education, telehealth services and remote work opportunities. Key components of the new network include Adtran’s AI-driven Mosaic One Device Manager and its Oscilloquartz timing and synchronization technology. Adtran’s partner, Netceed, a leading provider of materials, distribution and supply chain management solutions supporting the telecommunications and broadband industry, is

HiddenA line styled icon from Orion Icon Library.Eye